Without User Fees, OTC Monograph Changes Are Low Priority At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s work on time and extent applications and monograph updates is not supported by user fees, unlike its work in evaluating NDAs for some OTC drugs and for Rx products. The difference shows in the stalled process for approving new monograph ingredients, says the acting head of FDA’s OTC drugs office.
You may also be interested in...
NDAC Input Sought On Sunscreen Ingredient Data Necessary For Approval
FDA’s Nonprescription Drugs Advisory Committee will meet Sept. 4-5 to discuss the scope and safety of testing necessary for OTC sunscreen ingredients. The announcement comes after FDA earlier this year rejected time and extent applications to add new sunscreen actives to the OTC monograph.
Chronic Conditions Data Emphasize Need For Additional, Innovative OTCs
An NIH-funded study shows 92% of older consumers have chronic conditions, the primary target of FDA’s Nonprescription Safe Use Regulatory Expansion initiative to facilitate more Rx-to-OTC switches. The agency also extends the comment period for its initiative on making more ingredients available through the OTC monograph process.
With OTC Cialis Rights, Sanofi Launches Latest Salvo In Consumer Sector Battle
Sanofi gains rights from Eli Lilly & Co. to apply for OTC approval of Cialis in the U.S., Europe, Canada and Australia. Launching the first OTC product indicated for erectile dysfunction would mark another milestone in Sanofi CEO Chris Viebacher’s mission to move the firm into the neighborhood of global OTC leaders.